EPS high-end implies significant margin expansion; driven by cost-out actions over last two quarters and tariff mitigation (reshoring, supply chain rework, June price increase).
Q4 FCF down year-over-year due to inventory build from moving three large facilities (Belgium build-out, Buffalo closure); some cash costs from reorg/plant closures carry into Q1 2026.
R&D over 5% of sales expected next year; microfluidics (fluNI) is a pure R&D platform (inkjet, cosmetic/drug delivery), while MECO is additive immediately with cost overlap from Gravitec integration.
Mgmt stance: Bullish on guidance achievability (cost-out + tariff mitigation already underway); neutral on FCF (lumpy inventory, but cash impact ends by Q1 2026).
Q2 — Keith Housum
Topic: R&D as % of sales, tariff impact timing, end-market growth (printers/cartridges)
Key points:
R&D historically ~5% of sales; Q4 spike from acquisitions; mgmt has no target % — highly engineered products carry 10%+ R&D but yield 60-70% gross margins.
Short-term R&D may dip slightly (team merger), but long-term trend is increasing; R&D is not a cost-saving area.
Incremental tariff impact of $8M–$12M in 2026 over 2025; more weighted to first two quarters as price increases roll through; mitigation strategies are included in guidance.
Printers and cartridges are just under 40% of business; growth driven by wire markers for data centers (phenomenal) and aerospace/defense (defense particularly strong).
Mgmt stance: Bullish on R&D investment (drives high-margin products); neutral on tariff timing (nuanced, product-specific); bullish on end-market growth (data centers, defense).